Investing in North America

Fresenius Kabi maintains its unwavering commitment to investing in North American manufacturing and cutting-edge technology, in order to effectively meet the expanding demands of the market.

Drug shortages continue to present ongoing challenges to healthcare delivery in Canada, while the demand for pharmaceutical products continues to rise. Recognizing this, Fresenius Kabi has made significant investments in state-of-the-art production sites in North America to address these issues. Our aim is to ensure a continuous supply of high-quality products that meet the needs of both current and future customers.

Over the past five years, Fresenius Kabi has invested nearly $1 billion in expanding and modernizing our advanced pharmaceutical production and distribution facilities. We take pride in the fact that more than 70% of our pharmaceuticals are formulated, filled, and packaged within North America.

With a focus on supporting our customers in Canada, we strive to instill confidence in clinicians and their patients. We continuously work towards bringing new and innovative products to the market for physicians, pharmacists, nurses, and patients alike.

By making significant investments in North America, we aim to enhance patient access to vital medications while reducing vulnerability during periods of increased supply demands and other disruptions.